The Vertex Alumni: Where Are They Now?

Jaren Irene Madden, vice president, life sciences, Feinstein Kean Healthcare [Added: 11:30 am Eastern, 4/29/10]

Robert Mashal, CEO, NKT Therapeutics

Robert McKelvey, principal and creative director, McKelvey Design [Added: 5:10 pm, 6/1/10]

Hal Meyers, founder, ProXyChem

Manuel Navia, executive-in-residence, Oxford Bioscience Partners

Debra Peattie, director of strategy and planning, Cubist Pharmaceuticals

Vicki Sato, professor of management practice, Harvard Business School

Jeff Saunders, head of chemistry, Agios Pharmaceuticals

Robert Silverman, vice president and general counsel, Concert Pharmaceuticals

Nancy Stuart, chief operating officer, Concert Pharmaceuticals

Shin-San Michael Su, vice president of drug discovery, interim chief scientific officer, Agios Pharmaceuticals

Roger Tung, co-founder, president, CEO, Concert Pharmaceuticals

Jeff Williams, president and CEO, Addicere Pharmaceuticals

Robert Zelle, vice president of drug development, Concert Pharmaceuticals

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.